Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines

Leukemia

Volumn 11, Issue 12, 1997, Pages 2066-2074

  Consoli, U ^a,b   Van, N T ^a   Neamati, N ^a   Mahadevia, R ^a   Beran, M ^a   Zhao, S ^a   Andreeff, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Ospedale Ferrarotto   (Italy)

Author keywords

Mitoxantrone; Multidrug resistance; P glycoprotein

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DOXORUBICIN; GLYCOPROTEIN P; MITOXANTRONE; VERAPAMIL;

ARTICLE; CELL NUCLEUS; CELL STRAIN HL 60; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; PRIORITY JOURNAL;

EID: 0031435897     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400511     Document Type: Article

References (13)

1. van der Graaf WTA, de Vries EGE. Mitoxantrone: bluebeard for malignancies. Anti-Cancer Drugs 1990; 1: 109-125.
2. Albert DS, Peng Y, Bowden GT, Dalton WS, Makel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 1985; 3: 101-107.
3. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560-571.
4. Bezwoda WR, Bernasconi C, Hutchinson RM, Winfield DA, deBock R, Mandelli F. Mitoxantrone for refractory and relapsed acute leukemia. Cancer 1990; 66: 418-422.
5. Arlin ZA, Case DC Jr, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or doxorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990; 4: 177-183.
6. Bajetta E, Buzzoni R, Valagussa R, Bonadonna G. Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas. Am J Clin Oncol Cancer Clin Trials 1988; 11: 100-103.
7. Arlin ZA, Berman E, Jhanwar S, Gams R, Schoch I, Dukart G. Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone. Cancer Chemother Pharmacol 1986; 17: 189-190.
8. Smith PJ, Morgan SA, Fox ME, Watson JV. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol 1990; 40: 2069-2078.
9. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992; 31: 205-213.
10. Capolongo L, Belvedere G, D'Incalci M. DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells. Cancer Chemother Pharmacol 1990; 25: 430-434.
11. Jensen PB, Vindelov L, Roed H, Demant EJ, Sehested M, Skovsgaard T, Hansen HH. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer 1989; 60: 838-844.
12. Dalton WS, Cress AE, Alberts DS, Trent JM. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 1988; 48: 1882-1888.
13. Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res 1989; 49: 4542-4549.